Bristol Myers Squibb Reports Positive Interim Phase 3 ACTION-1 Results for RYZ101

Bristol Myers Squibb announced positive topline results from an interim analysis of the Phase 3 ACTION-1 study of RYZ101 in patients with GEP-NETs.